-
Something wrong with this record ?
Accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks) : an alternative in the treatment of locally advanced head and neck cancer
J. Kubes, J. Cvek, V. Vondracek, M. Pala, D. Feltl,
Language English Country Germany
Document type Journal Article
NLK
ProQuest Central
from 1997-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2006-08-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 1997-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-01-01 to 1 year ago
Public Health Database (ProQuest)
from 1997-01-01 to 1 year ago
- MeSH
- Adult MeSH
- Radiotherapy, Conformal methods MeSH
- Middle Aged MeSH
- Humans MeSH
- Hypopharyngeal Neoplasms mortality pathology radiotherapy MeSH
- Nasopharyngeal Neoplasms mortality pathology radiotherapy MeSH
- Mouth Neoplasms mortality pathology radiotherapy MeSH
- Follow-Up Studies MeSH
- Otorhinolaryngologic Neoplasms mortality pathology radiotherapy MeSH
- Disease-Free Survival MeSH
- Radiation Injuries etiology MeSH
- Radiotherapy, Intensity-Modulated methods MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Feasibility Studies MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND AND PURPOSE: To present the feasibility and results of accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks) in the treatment of locally advanced head and neck cancer. PATIENTS AND METHODS: A total of 65 patients were treated between June 2006 and August 2009. The distribution of clinical stages was as follows: II 11%, III 23%, IV 61%, and not defined 5%. RESULTS: The median follow-up was 30.5 months. The treatment plan was completed in 94% of patients. Patients were treated using the conformal or intensity-modulated radiotherapy (IMRT) technique. The median overall treatment time was 37 days (13-45 days). The mean radiotherapy dose was 68.4 Gy (16-74 Gy). Overall survival was 69% after 2 years. Disease-free survival was 62% after 2 years. Acute toxicity ≥ grade 3(RTOG scale) included mucositis (grade 3: 42.6%), pharynx (grade 3: 42.3%), skin (grade 3: 9.5%), larynx (grade 3: 4%), while late toxicity affected skin (grade 3: 6.25%) and salivary glands (grade 3: 3.7%). CONCLUSION: Accelerated radiotherapy with concomitant boost technique is feasible in patients with locally advanced head and neck cancer, has an acceptable toxicity profile, and yields promising treatment results.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12028041
- 003
- CZ-PrNML
- 005
- 20121210111253.0
- 007
- ta
- 008
- 120817e20110923gw f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00066-011-2246-2 $2 doi
- 035 __
- $a (PubMed)21947124
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Kubes, Jiri $u Institute of Radiation Oncology, Prague, The Czech Republic. jiri.kubes@fnb.cz
- 245 10
- $a Accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks) : an alternative in the treatment of locally advanced head and neck cancer / $c J. Kubes, J. Cvek, V. Vondracek, M. Pala, D. Feltl,
- 520 9_
- $a BACKGROUND AND PURPOSE: To present the feasibility and results of accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks) in the treatment of locally advanced head and neck cancer. PATIENTS AND METHODS: A total of 65 patients were treated between June 2006 and August 2009. The distribution of clinical stages was as follows: II 11%, III 23%, IV 61%, and not defined 5%. RESULTS: The median follow-up was 30.5 months. The treatment plan was completed in 94% of patients. Patients were treated using the conformal or intensity-modulated radiotherapy (IMRT) technique. The median overall treatment time was 37 days (13-45 days). The mean radiotherapy dose was 68.4 Gy (16-74 Gy). Overall survival was 69% after 2 years. Disease-free survival was 62% after 2 years. Acute toxicity ≥ grade 3(RTOG scale) included mucositis (grade 3: 42.6%), pharynx (grade 3: 42.3%), skin (grade 3: 9.5%), larynx (grade 3: 4%), while late toxicity affected skin (grade 3: 6.25%) and salivary glands (grade 3: 3.7%). CONCLUSION: Accelerated radiotherapy with concomitant boost technique is feasible in patients with locally advanced head and neck cancer, has an acceptable toxicity profile, and yields promising treatment results.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a studie proveditelnosti $7 D005240
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory hypofaryngu $x mortalita $x patologie $x radioterapie $7 D007012
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a nádory úst $x mortalita $x patologie $x radioterapie $7 D009062
- 650 _2
- $a nádory nosohltanu $x mortalita $x patologie $x radioterapie $7 D009303
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a otorinolaryngologické nádory $x mortalita $x patologie $x radioterapie $7 D010039
- 650 _2
- $a radiační poranění $x etiologie $7 D011832
- 650 _2
- $a konformní radioterapie $x metody $7 D020266
- 650 _2
- $a radioterapie s modulovanou intenzitou $x metody $7 D050397
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Cvek, Jakub
- 700 1_
- $a Vondracek, Vladimir
- 700 1_
- $a Pala, Miloslav
- 700 1_
- $a Feltl, David
- 773 0_
- $w MED00010658 $t Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] $x 1439-099X $g Roč. 187, č. 10 (20110923), s. 651-5
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21947124 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20121210111330 $b ABA008
- 999 __
- $a ok $b bmc $g 950083 $s 785387
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 187 $c 10 $d 651-5 $e 20110923 $i 1439-099X $m Strahlentherapie und Onkologie $n Strahlenther Onkol $x MED00010658
- LZP __
- $a Pubmed-20120817/11/04
